A Phase 3 interventional study of EB-1020 (Centanafadine) 164.4 mg and EB-1020 (Centanafadine) 328.8 mg in Attention Deficit Hyperactivity Disorder (ADHD), sponsored by Otsuka Pharmaceutical Co., Ltd.. Recruiting at 1 site in Japan. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing centanafadine in Attention Deficit Disorder with Hyperactivity — 5 open to participants now, 5 under way, 5 of them phase 3. centanafadine · Attention Deficit Disorder with Hyperactivity.
Among the 20 studies testing centanafadine in Attention Deficit Disorder with Hyperactivity, this one is the 10th largest by planned enrollment, is one of 5 that started in 2025, is one of 10 in phase 3, and was the 13th registered.
1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.
Browse Attention Deficit Disorder with Hyperactivity studies →5 of the 20 studies testing centanafadine in Attention Deficit Disorder with Hyperactivity are open now, in 2 countries. Recruiting first, the newest first:
Otsuka Pharmaceutical Development & Commercialization, Inc. · Sites in United States
Ages 18–65
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 6–17
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 6–17
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 18–55
By country, each count listing its studies:
centanafadine: first FDA approval 2026 (SIMTRIYO). What it is approved for, and how studies give it, is on its page →
Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 3 · Phase 3 12
First in 2014; this study’s year is marked. 5 started in 2025.
This study's planned enrollment of 180 is above the median of 71 across 1,437 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.
Median enrollment 180 across the 20 interventional studies. Of the 15 that completed or were terminated, 4 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 20 have an industry lead sponsor. The 2 most frequent:
This study is registered under Otsuka Pharmaceutical Co., Ltd., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
25 studies in Attention Deficit Disorder with Hyperactivity by Otsuka Holdings Co., Ltd.: 5 open now, 5 under way, 5 of them phase 3. Of 20 finished, 8 (40%) have results posted.
Among the 25 studies in Attention Deficit Disorder with Hyperactivity by Otsuka Holdings Co., Ltd., this one is the 12th largest by planned enrollment, is one of 5 that started in 2025, is one of 10 in phase 3, and was the 18th registered.
Otsuka Holdings Co., Ltd.’s Attention Deficit Disorder with Hyperactivity studies by the year they started, since 2010.
3 of the studies testing centanafadine in Attention Deficit Disorder with Hyperactivity that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07759154Phase 3Otsuka Pharmaceutical Development & Commercialization, Inc.A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation | 2027-05-27 |
| NCT07087327Phase 3Otsuka Pharmaceutical Co., Ltd.A Long-term Trial of EB-1020 in Pediatric Patients With ADHD | 2027-08 |
| NCT07086313Phase 3Otsuka Pharmaceutical Co., Ltd.A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 20 studies testing centanafadine in Attention Deficit Disorder with Hyperactivity, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 25 in Attention Deficit Disorder with Hyperactivity:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety of long-term administration of mainly high doses of EB-1020 over 52 weeks in patients who have completed the double-blind trial (405-102-00112) conducted in Japan
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants who have a significant risk of committing suicide in the opinion of the investigator or subinvestigator, or based on the following evidence:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: EB-1020 (Centanafadine) 164.4 mg
Drug: EB-1020 (Centanafadine) 328.8 mg
164.4 mg, capsule, oral, once daily, for 52 weeks
328.8 mg, capsule, oral, once daily, for 52 weeks
Number of Patients Experiencing Treatment-Emergent Adverse Events (TEAEs)
An AE is defined as any untoward medical occurrence in a patient or clinical trial participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. TEAEs are defined as AEs with an onset date on or after the first dose of IMP. They are all adverse events that started after the start of centanafadine; or if the event was continuous from baseline and was worsening, serious, study drug-related, or resulted in death, discontinuation, interruption or reduction of study therapy.
Time frame: Baseline, week52
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article Publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com.
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Dec 2027, 30 months after the start.
Of 66 industry-sponsored phase 3 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's planned 30 months is above that.
Counting every sponsor, half of 80 studies reached it within 14 months; a quarter within 7 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Centanafadine
Attention Deficit Disorder with Hyperactivity →
Otsuka Pharmaceutical Co., Ltd. →